PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity
Vancouver, British Columbia–(Newsfile Corp. – July 15, 2020) – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (« PreveCeutical »), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program.
This update of PreveCeutical’s Dual Gene Therapy Program, (see earlier release on January 14, 2020, and June 29, 2020), has identified a promising modified delivery vector ready for possible pre-clinical experiments. It is based on stable siRNA (small interfering ribonucleic acid) incorporation within the delivery vehicle, with strong cell entry and cargo release, and minimal toxicity. These delivery systems have the potential to combine the benefits of silencing RNAi (ribonucleic acid interference) and modified delivery vectors.
PreveCeutical will now proceed with the optimization of the delivery system that will be tested in animal models disease.
PreveCeutical’s Chair and Chief Executive Officer, Mr. Stephen Van Deventer, commented, « The current results PreveCeutical has received is very exciting to us and shows a very high probability of success that will now allow us to move to the completion stage of the program. »
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.
PreveCeutical aims to be a leader in preventive health sciences. PreveCeutical’s current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders; Nature Identical™ peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations firstname.lastname@example.org
This news release contains forward-looking statements and forward-looking information (collectively, « forward-looking statements ») within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of one aspect of the current phase of the Dual Gene Therapy Program, the efficacy of PreveCeutical’s products, matters related to PreveCeutical’s current and planned research and development programs, including the Dual Gene Therapy Program, the efficacy of the panel of siRNA constructs and the efficacy, biostability and potency of the Smart-siRNAs, PreveCeutical’s anticipated future business plans and its prospect of success in executing thereon. Often, but not always, forward-looking statements can be identified by words such as « will », « plans », « expects », « may », « intends », « anticipates », « believes », « proposes » or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding PreveCeutical, including expected growth, results of operations and research and development activities (including in respect of the successful completion of the Dual Gene Therapy Program and one aspect of its current phase), performance, industry trends, growth opportunities, and that PreveCeutical will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.
Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the completion of the Dual Gene Therapy Program and one aspect of its current phase, actual results of research and development programs, the inability of PreveCeutical, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, including the Dual Gene Therapy Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology, pharmaceutical or cannabis industry may also adversely affect the future results or performance of PreveCeutical. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, PreveCeutical assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although PreveCeutical believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by PreveCeutical from time-to-time. These reports and PreveCeutical’s filings are available at www.sedar.com.
Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.